Supportive Therapy in OncologySupportive Therapy in OncologyПоддерживающая терапия в онкологии3034-24733034-3178Publishing House ABV Press3610.17650/3034-2473-2024-1-3-13-25ORIGINAL REPORTSОРИГИНАЛЬНЫЕ СТАТЬИTolerability of dose-dense and standard regimens of neoadjuvant chemotherapy in estrogen receptor-positive/HER2-negative breast cancer: results of a prospective observational studyПереносимость дозоуплотненного и стандартного режимов неоадъювантной химиотерапии при эстроген-рецептор-положительном/HER2-отрицательном раке молочной железы: результаты проспективного наблюдательного исследованияhttps://orcid.org/0000-0003-4447-9458OrlovaR. V.ОрловаР. В.
Russian Federation

7–9 Universitetskaya Naberezhnaya, Saint Petersburg 199034

56 Prospekt Veteranov, Saint Petersburg 198255

199034 Санкт-Петербург, Университетская набережная, 7–9

198255 Санкт-Петербург, пр-кт Ветеранов, 56

https://orcid.org/0000-0003-1321-3657VakhitovaA. A.ВахитоваА. А.
Russian Federation

Almira Alberdovna Vakhitova

56 Prospekt Veteranov, Saint Petersburg 198255

Альмира Альбердовна Вахитова

198255 Санкт-Петербург, пр-кт Ветеранов, 56

alberdovna@mail.ruhttps://orcid.org/0000-0002-2105-2251TopuzovE. E.ТопузовЭ. Э.
Russian Federation

7–9 Universitetskaya Naberezhnaya, Saint Petersburg 199034

56 Prospekt Veteranov, Saint Petersburg 198255

41 Kirochnaya St., Saint Petersburg 191015

199034 Санкт-Петербург, Университетская набережная, 7–9

198255 Санкт-Петербург, пр-кт Ветеранов, 56

191015 Санкт-Петербург, ул. Кирочная, 41

https://orcid.org/0000-0002-8404-4232GluzmanM. I.ГлузманМ. И.
Russian Federation

7–9 Universitetskaya Naberezhnaya, Saint Petersburg 199034

56 Prospekt Veteranov, Saint Petersburg 198255

199034 Санкт-Петербург, Университетская набережная, 7–9

198255 Санкт-Петербург, пр-кт Ветеранов, 56

https://orcid.org/0000-0001-6933-0030SerikovaE. L.СериковаЕ. Л.
Russian Federation

56 Prospekt Veteranov, Saint Petersburg 198255

198255 Санкт-Петербург, пр-кт Ветеранов, 56

https://orcid.org/0009-0006-5556-215XPetrenkoM. A.ПетренкоМ. А.
Russian Federation

56 Prospekt Veteranov, Saint Petersburg 198255

198255 Санкт-Петербург, пр-кт Ветеранов, 56

https://orcid.org/0000-0003-4473-3049BembeevaL. V.БембееваЛ. В.
Russian Federation

56 Prospekt Veteranov, Saint Petersburg 198255

198255 Санкт-Петербург, пр-кт Ветеранов, 56

https://orcid.org/0009-0006-9576-8419KrasnoperovaA. V.КраснопероваА. В.
Russian Federation

56 Prospekt Veteranov, Saint Petersburg 198255

198255 Санкт-Петербург, пр-кт Ветеранов, 56

https://orcid.org/0009-0000-4874-4429KotkovaT. N.КотковаТ. Н.
Russian Federation

56 Prospekt Veteranov, Saint Petersburg 198255

198255 Санкт-Петербург, пр-кт Ветеранов, 56

https://orcid.org/0000-0001-7111-1507AndrosovaA. V.АндросоваА. В.
Russian Federation

7–9 Universitetskaya Naberezhnaya, Saint Petersburg 199034

56 Prospekt Veteranov, Saint Petersburg 198255

199034 Санкт-Петербург, Университетская набережная, 7–9

198255 Санкт-Петербург, пр-кт Ветеранов, 56

https://orcid.org/0009-0008-2518-3778SharvashidzeI. O.ШарвашидзеИ. О.
Russian Federation

56 Prospekt Veteranov, Saint Petersburg 198255

198255 Санкт-Петербург, пр-кт Ветеранов, 56

Saint Petersburg State UniversityФГБОУ ВО «Санкт-Петербургский государственный университет»Saint Petersburg City Clinical Oncology DispensaryСПб ГБУЗ «Городской клинический онкологический диспансер»I.I. Mechnikov North-Western State Medical University, Ministry of Health of RussiaФГБОУ ВО «Северо-Западный государственный медицинский университет им. И.И. Мечникова» Минздрава России151220241313252201202522012025Copyright ©; 2024, Orlova R.V., Vakhitova A.A., Topuzov E.E., Gluzman M.I., Serikova E.L., Petrenko M.A., Bembeeva L.V., Krasnoperova A.V., Kotkova T.N., Androsova A.V., Sharvashidze I.O.Copyright ©; 2024, Орлова Р.В., Вахитова А.А., Топузов Э.Э., Глузман М.И., Серикова Е.Л., Петренко М.А., Бембеева Л.В., Красноперова А.В., Коткова Т.Н., Андросова А.В., Шарвашидзе И.О.2024Orlova R.V., Vakhitova A.A., Topuzov E.E., Gluzman M.I., Serikova E.L., Petrenko M.A., Bembeeva L.V., Krasnoperova A.V., Kotkova T.N., Androsova A.V., Sharvashidze I.O.Орлова Р.В., Вахитова А.А., Топузов Э.Э., Глузман М.И., Серикова Е.Л., Петренко М.А., Бембеева Л.В., Красноперова А.В., Коткова Т.Н., Андросова А.В., Шарвашидзе И.О.https://creativecommons.org/licenses/by/4.0https://stio.abvpress.ru/jour/article/view/36

Background. Given the high prevalence of hormone-sensitive breast cancer in Russia and around the world, it is extremely important to address the issue of indications for neoadjuvant (NACT) or adjuvant chemotherapy, as well as the scope and regimens of treatment. The article presents the results of our own study, considers the problems of toxicity and tolerability of dose-dense and standard NACT regimens.

Aim. To study the tolerability of dose-dense and standard NACT regimens.

Materials and methods. The prospective study included 109 patients. 53 patients received dose-dense NACT as preoperative treatment, 56 – the standard NACT regimen.

Results. In dose-dense NACT, the frequency and severity of anemia (p = 0.038), hepatotoxicity (p <0.001), peripheral polyneuropathy (p <0.001) increased, but the frequency of delayed start of the cycle in general (p = 0.012) and delay due to neutropenia (p <0.001) decreased.

Conclusion. When planning preventive chemotherapy in the treatment of breast cancer (NACT or adjuvant chemotherapy), it is necessary to take into account not only the oncological results in increasing recurrence-free and overall survival, but also the tolerability of therapy.

Введение. С учетом высокой распространенности гормоночувствительного рака молочной железы как в России, так и в мире крайне актуально решение вопросов о показаниях к проведению неоадъювантной (НАХТ) или адъювантной химиотерапии, а также объеме и режимах проводимого лечения. В статье представлены результаты собственного исследования, освещены вопросы токсичности и переносимости дозоуплотненных и стандартных режимов НАХТ.

Цель исследования – изучить переносимость дозоуплотненных и стандартных режимов НАХТ.

Материалы и методы. В проспективное исследование включены 109 пациенток: 53 получили в качестве предоперационного лечения дозоуплотненный режим НАХТ, 56 – стандартный режим.

Результаты. При дозоуплотненных режимах НАХТ увеличивались частота и выраженность анемии (р = 0,038), гепатотоксичности (р <0,001), периферической полинейропатии (р <0,001), но снижалась частота отсрочки начала цикла в целом (р = 0,012) и по причине нейтропении (р <0,001).

Заключение. При планировании профилактической химиотерапии в лечении рака молочной железы (НАХТ или адъювантная химиотерапия) необходимо учитывать не только онкологические результаты по увеличению безрецидивной и общей выживаемости, но и переносимость терапии.

breast cancerdose-dense neoadjuvant chemotherapystandard neoadjuvant chemotherapygranulocyte colony-stimulating factorрак молочной железыдозоуплотненный режим неоадъювантной химиотерапиистандартный режим неоадъювантной химиотерапиигранулоцитарный колониестимулирующий фактор1. Zhou W., Chen S., Xu F., Zeng X. Survival benefit of pure dosedense chemotherapy in breast cancer: a meta-analysis of randomized controlled trials. World J Surg Oncol 2018;16(1):144. DOI: 10.1186/s12957-018-1424-4Zhou W., Chen S., Xu F., Zeng X. Survival benefit of pure dosedense chemotherapy in breast cancer: a meta-analysis of randomized controlled trials. World J Surg Oncol 2018;16(1):144. DOI: 10.1186/s12957-018-1424-42. World Health Organization. Breast Cancer. 2018. Available at: https://www.who.int/cancer/prevention/diagnosis-screening/breast-cancer/en/ (accessed 27.12.2019).World Health Organization. Breast Cancer. 2018. Available at: https://www.who.int/cancer/prevention/diagnosis-screening/breast-cancer/en/ (accessed 27.12.2019).3. Cardoso F., Kyriakides S., Ohno S. et al. Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up [published correction appears in Ann Oncol 2021;32(2):284]. Ann Oncol 2019;30(10):1674. DOI: 10.1093/annonc/mdz189Cardoso F., Kyriakides S., Ohno S. et al. Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up [published correction appears in Ann Oncol 2021;32(2):284]. Ann Oncol 2019;30(10):1674. DOI: 10.1093/annonc/mdz1894. Li J.J., Shao Z.M. Endocrine therapy as adjuvant or neoadjuvant therapy for breast cancer: selecting the best agents, the timing and duration of treatment. Chin Clin Oncol 2016;5(3):40. DOI: 10.21037/cco.2016.03.24Li J.J., Shao Z.M. Endocrine therapy as adjuvant or neoadjuvant therapy for breast cancer: selecting the best agents, the timing and duration of treatment. Chin Clin Oncol 2016;5(3):40. DOI: 10.21037/cco.2016.03.245. Jia Y., Song Y., Dong G. et al. Aberrant regulation of RAD51 promotes resistance of neoadjuvant endocrine therapy in ER-positive breast cancer. Sci Rep 2019;9(1):12939. DOI: 10.1038/s41598-019-49373-wJia Y., Song Y., Dong G. et al. Aberrant regulation of RAD51 promotes resistance of neoadjuvant endocrine therapy in ER-positive breast cancer. Sci Rep 2019;9(1):12939. DOI: 10.1038/s41598-019-49373-w6. Kurozumi S., Yamaguchi Y., Matsumoto H. et al. Utility of Ki67 labeling index, cyclin D1 expression, and ER-activity level in postmenopausal ER-positive and HER2-negative breast cancer with neoadjuvant chemo-endocrine therapy. PLoS One 2019;14(5):e0217279. DOI: 10.1371/journal.pone.0217279Kurozumi S., Yamaguchi Y., Matsumoto H. et al. Utility of Ki67 labeling index, cyclin D1 expression, and ER-activity level in postmenopausal ER-positive and HER2-negative breast cancer with neoadjuvant chemo-endocrine therapy. PLoS One 2019;14(5):e0217279. DOI: 10.1371/journal.pone.02172797. Newman L.A. Epidemiology of locally advanced breast cancer. Semin Radiat Oncol 2009;19(4):195–203. DOI: 10.1016/j.semradonc.2009.05.003Newman L.A. Epidemiology of locally advanced breast cancer. Semin Radiat Oncol 2009;19(4):195–203. DOI: 10.1016/j.semradonc.2009.05.0038. Tryfonidis K., Senkus E., Cardoso M.J., Cardoso F. Management of locally advanced breast cancer-perspectives and future directions [published correction appears in Nat Rev Clin Oncol 2015;12(6):312]. Nat Rev Clin Oncol 2015;12(3):147–62. DOI: 10.1038/nrclinonc.2015.13Tryfonidis K., Senkus E., Cardoso M.J., Cardoso F. Management of locally advanced breast cancer-perspectives and future directions [published correction appears in Nat Rev Clin Oncol 2015;12(6):312]. Nat Rev Clin Oncol 2015;12(3):147–62. DOI: 10.1038/nrclinonc.2015.139. El Saghir N.S., Adebamowo C.A., Anderson B.O. et al. Breast cancer management in low resource countries (LRCs): consensus statement from the breast health global initiative. Breast 2011;20(Suppl 2):S3–11. DOI: 10.1016/j.breast.2011.02.006El Saghir N.S., Adebamowo C.A., Anderson B.O. et al. Breast cancer management in low resource countries (LRCs): consensus statement from the breast health global initiative. Breast 2011;20(Suppl 2):S3–11. DOI: 10.1016/j.breast.2011.02.00610. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG); Peto R., Davies C., Godwin J. et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials. Lancet 2012;379(9814):432–44. DOI: 10.1016/S0140-6736(11)61625-5Early Breast Cancer Trialists’ Collaborative Group (EBCTCG); Peto R., Davies C., Godwin J. et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials. Lancet 2012;379(9814):432–44. DOI: 10.1016/S0140-6736(11)61625-511. Citron M.L., Berry D.A., Cirrincione C. et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21(8):1431–9. DOI: 10.1200/jco.2003.09.081Citron M.L., Berry D.A., Cirrincione C. et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21(8):1431–9. DOI: 10.1200/jco.2003.09.08112. Foukakis T., von Minckwitz G., Bengtsson N.O. et al. Effect of tailored dose-dense chemotherapy vs standard 3-weekly adjuvant chemotherapy on recurrence-free survival among women with high-risk early breast cancer: a randomized clinical trial. JAMA 2016;316(18):1888–96. DOI: 10.1001/jama.2016.15865Foukakis T., von Minckwitz G., Bengtsson N.O. et al. Effect of tailored dose-dense chemotherapy vs standard 3-weekly adjuvant chemotherapy on recurrence-free survival among women with high-risk early breast cancer: a randomized clinical trial. JAMA 2016;316(18):1888–96. DOI: 10.1001/jama.2016.1586513. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. Lancet 2019;393(10179):1440–52. DOI: 10.1016/S0140-6736(18)33137-4Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. Lancet 2019;393(10179):1440–52. DOI: 10.1016/S0140-6736(18)33137-414. Podsada K., Ryan J.C., Orbaugh K. Optimizing palbociclib therapy across the age spectrum: hypothetical, illustrative case scenarios in HR+, HER2-metastatic breast cancer. J Adv Pract Oncol 2020;11(7):700–19. DOI: 10.6004/jadpro.2020.11.7.5Podsada K., Ryan J.C., Orbaugh K. Optimizing palbociclib therapy across the age spectrum: hypothetical, illustrative case scenarios in HR+, HER2-metastatic breast cancer. J Adv Pract Oncol 2020;11(7):700–19. DOI: 10.6004/jadpro.2020.11.7.515. Danese M.D., O’Malley C., Lindquist K. et al. An observational study of the prevalence and incidence of comorbid conditions in older women with breast cancer. Ann Oncol 2012;23:1756e65. DOI: 10.1093/annonc/mdr486Danese M.D., O’Malley C., Lindquist K. et al. An observational study of the prevalence and incidence of comorbid conditions in older women with breast cancer. Ann Oncol 2012;23:1756e65. DOI: 10.1093/annonc/mdr48616. Louwman W.J., Janssen-Heijnen M.L., Houterman S. et al. Less extensive treatment and inferior prognosis for breast cancer patient with comorbidity: a population-based study. Eur J Cancer 2005;41(5):779–85. DOI: 10.1016/j.ejca.2004.12.025Louwman W.J., Janssen-Heijnen M.L., Houterman S. et al. Less extensive treatment and inferior prognosis for breast cancer patient with comorbidity: a population-based study. Eur J Cancer 2005;41(5):779–85. DOI: 10.1016/j.ejca.2004.12.02517. Edwards M.J., Campbell I.D., Lawrenson R.A., Kuper-Hommel M.J. Influence of comorbidity on chemotherapy use for early breast cancer: systematic review and meta-analysis. Breast Canc Res Treat 2017;165(1):17–39. DOI: 10.1007/s10549-017-4295-4Edwards M.J., Campbell I.D., Lawrenson R.A., Kuper-Hommel M.J. Influence of comorbidity on chemotherapy use for early breast cancer: systematic review and meta-analysis. Breast Canc Res Treat 2017;165(1):17–39. DOI: 10.1007/s10549-017-4295-418. Søgaard M., Thomsen R.W., Bossen K.S. et al. The impact of comorbidity on cancer survival: a review. Clin Epidemiol 2013;5(Suppl 1):3–29. DOI: 10.2147/CLEP.S47150Søgaard M., Thomsen R.W., Bossen K.S. et al. The impact of comorbidity on cancer survival: a review. Clin Epidemiol 2013;5(Suppl 1):3–29. DOI: 10.2147/CLEP.S4715019. Gelmon K., Walshe J.M., Mahtani R. et al. Efficacy and safety of palbociclib in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with preexisting conditions: a post hoc analysis of PALOMA-2. Breast 2021;59:321–6. DOI: 10.1016/j.breast.2021.07.017Gelmon K., Walshe J.M., Mahtani R. et al. Efficacy and safety of palbociclib in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with preexisting conditions: a post hoc analysis of PALOMA-2. Breast 2021;59:321–6. DOI: 10.1016/j.breast.2021.07.01720. Riseberg D. Treating elderly patients with hormone receptor-positive advanced breast cancer. Clin Med Insights Oncol 2015;9:65–73. DOI: 10.4137/CMO.S26067Riseberg D. Treating elderly patients with hormone receptor-positive advanced breast cancer. Clin Med Insights Oncol 2015;9:65–73. DOI: 10.4137/CMO.S26067